NovaBridge Biosciences Appoints Emmett T. Cunningham Jr., MD, PhD, MPH, As Vice Chairman Of Board And R&D Committee Member

NovaBridge Biosciences, a global biotechnology platform company focused on accelerating access to innovative medicines, announced the appointment of Emmett T. Cunningham, Jr., MD, PhD, MPH, as Vice Chairman of its Board of Directors. Dr. Cunningham, Co-Founder and Executive Chairman of Visara, Inc., will also join the Research and Development Committee of the NovaBridge Board.

Dr. Cunningham brings more than 20 years of leadership experience in the biopharmaceutical industry, including senior roles in venture capital as Senior Managing Director at Blackstone Group L.P. and Managing Director at Clarus Ventures, LLC. He also has extensive industry experience, having held senior leadership positions at Eyetech, Inc., and Pfizer. In addition, Dr. Cunningham is a globally recognized specialist in infectious and inflammatory eye disease, with over 450 co-authored publications, and has broad experience serving on corporate boards.

Fu Wei, Executive Chairman of NovaBridge, welcomed Dr. Cunningham to the Board, highlighting his distinguished career as a physician, entrepreneur, and investor. Mr. Wei noted that Dr. Cunningham’s expertise in accelerating early-stage programs across multiple therapeutic areas complements NovaBridge’s hub-and-spoke business model and reinforces the company’s focus on addressing unmet patient needs while driving long-term shareholder value.

Dr. Cunningham expressed enthusiasm about joining NovaBridge as Vice Chairman, emphasizing the potential of the company’s unique global biotech platform. Having previously collaborated with Fu Wei and the NovaBridge leadership team through the founding of Visara, he highlighted his familiarity with the company’s operations and its capacity to bridge gaps between patient needs and transformative therapies. 

Dr. Cunningham also noted his intention to work closely with Fu Wei and Sean Fu, PhD, MDA, Chief Executive Officer of NovaBridge, to bring an entrepreneurial perspective to the Board while leveraging the company’s scientific capabilities and capital efficiency to advance breakthrough medicines and generate sustainable shareholder value.